SRR25617852
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.380
- PANCREAS_BETA_CELLS+0.350
- SPERMATOGENESIS+0.320
- G2M_CHECKPOINT+0.220
- KRAS_SIGNALING_DN+0.200
- INTERFERON_ALPHA_RESPONSE+0.140
- DNA_REPAIR+0.050
- MYC_TARGETS_V1+0.040
- MYC_TARGETS_V2+0.000
- APICAL_SURFACE-0.040
Top 10 suppressed
- TGF_BETA_SIGNALING-0.560
- UV_RESPONSE_DN-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- NOTCH_SIGNALING-0.470
- TNFA_SIGNALING_VIA_NFKB-0.410
- ADIPOGENESIS-0.390
- APOPTOSIS-0.390
- APICAL_JUNCTION-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- MYOGENESIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617910 | — | B | 0.924 |
| 2 | MDT-AP-1162 | Med | Medulloblastoma | 0.916 |
| 3 | SRR25617851 | — | B | 0.906 |
| 4 | SRR25617831 | — | D | 0.898 |
| 5 | SRR1313096 | — | B | 0.890 |
| 6 | SRR934790 | — | — | 0.886 |
| 7 | SRR8526725 | — | cohortSQ2 | 0.877 |
| 8 | C3N-02728 | — | cohortMD1 | 0.876 |
| 9 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.872 |
| 10 | TCGA-E9-A3HO-01A-11R-A213-07 | — | B | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |